Best practice model for the disclosure of results and transparent information on clinical trials

Open access to clinical trial information is becoming increasingly important to policymakers, healthcare professionals, patients and the general public. This document sets out guidance for the pharmaceutical industry to encourage greater transparency about the information gained from clinical trials. It is a working document that will be will be subject to regular review.